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Abstract
Background: The aberrant expression of miR-23b is involved in the development and progression of cancer. The
aim of this study was to evaluate the potential role of methylation in the silencing of miR-23b in cervical cancer cell
lines and to determine its expression in stages of malignant progression and in cervical cancer tissues HPV16-positive.
Methods: The methylation of the miR-23b promoter was determined in HeLa, SiHa, CaSki and C33A cells using a
Human Cancer miRNA EpiTectMethyl II Signature PCR Array®. The cells were treated with 5-Aza-2′-deoxycytidine, and
the expression of miR-23b, uPa, c-Met and Zeb1 was determined by qRT-PCR. miR-92a and GAPDH were used as
controls. The expression of miR-23b was determined in cervical scrapes and biopsies of women without squamous
intraepithelial lesions, with precursor lesions and with cervical cancer, all were HPV16-positive. The Fisher exact and
Mann–Whitney tests were used to compare the differences of the expression of miR-23b, uPa, c-Met and Zeb1 among
cell groups, and the difference among patients, respectively. The association between the expression of miR-23b and
cervical cancer was determined by logistic regression with a confidence level of 95 %. A value of p < 0.05 was
considered statistically significant.
Results: In C33A, HeLa and CaSki cells, methylation was associated with decreased expression of miR-23b. After
treatment with 5-Aza-CdR, the expression of miR-23b increased in all cell lines and the expression of c-Met decreased
in HeLa cells, while uPa and Zeb1 decreased in C33A and CaSki cells. In SiHa cells the expression of uPa, c-Met and Zeb1
increased. The expression of miR-23b decreased in relation to the increase in the severity of the lesion and was
significantly lower in cervical cancer. In women with premalignant lesions HPV16-positive, decreased levels of miR-23b
increased the risk of cervical cancer (OR = 36, 95 % CI = 6.7-192.6, p < 0.05).
Conclusions: The results suggest that the expression of miR-23b is regulated by the methylation of its promoter and is
possible that this microRNA influence the expression of uPa, c-Met and Zeb1 in cervical cancer cells lines. In women
with premalignant lesions and cervical cancer infected with HPV16, the expression level of miR-23b agree with a tumor
suppressor gene.
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Background
The high-risk human papillomavirus (HR-HPV) causes
cervical cancer [1], and this infection is also associated
with precancerous lesions of the cervix [2, 3]. In
addition, other molecular events such as genetic and epi-
genetic abnormalities also contribute to the transform-
ation and immortalization of epithelial cells infected
with HR-HPV [4].
The miRNAs can regulate 60 to 90 % of the protein-
encoding genes and a single miRNA can regulate, dir-
ectly or indirectly, the expression of hundreds of target
mRNAs [5–7]. The aberrant expression of miRNAs has
been associated with the maintenance of the undifferen-
tiated state of cancer cells [8].
miRNA biogenesis is highly regulated by multiple pro-
cesses. Approximately 40 % of human miRNAs are orga-
nized in conserved clusters, with distances of at least
5000 bp between them [9], and these miRNAs are co-
transcribed as discrete polycistronic pri-miRNAs [6, 10].
Although the miR-23b gene is encoded in the human
chromosome 9q22.32 in a cluster that includes miR-24-1
and miR-27b, the mature sequences of each miRNA are
differentially expressed [11, 12].
The altered expression of miR-23b has been found to
be associated with many types of cancer. In breast can-
cer, the overexpression of miR-23b is correlated with cell
proliferation and metastasis, and is thus recognized as
an oncogene [13]. In contrast, the expression of miR-
23b in breast cancer increases the formation of focal ad-
hesions and cell-cell junctions, thereby indicating a
metastatic suppressor role for this microRNA [14]. Fur-
thermore, the expression of miR-23b has been found to
be decreased in castration-resistant prostate cancer tis-
sue, while its overexpression suppresses migration and
invasion. Thus, miR-23b is also recognized as a meta-
static suppressor in this type of cancer [6, 7, 9].
The expression of miR-23b is decreased in HR-HPV
positive cervical cancer tissue and cell lines [15], and it
is associated with the overexpression of the urokinase-
type plasminogen activator (uPA), which is target gene
of this miRNA [16]. uPA has been directly associated
with migration and invasion in cervical cancer [17]. Al-
though it is proposed that the E6 oncoprotein of HR-
HPV regulates the expression of miR-23b in cervical
cancer, this mechanism has not been fully elucidated.
A significant number of miRNAs are embedded in
CpG islands and that they are targets of epigenetic regu-
lation [8, 17–19]. In human neoplasia, hypermethylation
of CpG sites is associated with transcriptional silencing
of tumor suppressor genes and genes that encode miR-
NAs [20]. There is evidence that miR-23b is subjected to
epigenetic silencing in glioblastoma and prostate cancer
[7, 8]. Interestingly, it has been suggested that, HPV16 E6
increases the levels of DNA methyltransferase 1 (DNMT1)
by degradation of p53 in cervical cancer, causing hyperme-
thylation of miRNA genes, among others [21].
Is proposed that in cervical cancer the inhibition of
p53 expression by HR-HPV E6 contributes to the de-
creased expression of miR-23b. The presence of CpG
sites in the promoter sequence of miR-23b allows the
regulation of this miRNA by methylation. It is known
that epigenetic silencing of miRNAs is associated with
processes of invasion and metastasis. Identifying the
mechanism by which the expression of miR-23b is regu-
lated in cervical cancer will provide useful information to
increase the understanding of this pathology and to create
therapies targeting specific epigenetic modifications.
The objective of this research was to evaluate the po-
tential role of methylation in the silencing of miR-23b in
cervical cancer cell lines and to determine the pattern of
expression of this microRNA in cervical tissues of pa-
tients without squamous intraepithelial lesion (Non-SIL),
with precursor lesions and HPV16 cervical cancer. In
this study, we found decreased expression of miR-23b in
cervical tissue with premalignant lesions in cervical can-
cer and in cervical cancer cell lines. Treatment with 5′-
aza-2-deoxycytidine restored the expression of miR-23b
in C33A, HeLa and CaSki cells.
Results
Model of the elements regulating the expression of miR-23b
An extensive review of the literature was conducted for
the selection of miR-23b. We constructed a model of the
regulatory region of the miR-23b gene based on the in-
formation found. Some elements that may contribute to
the regulation of expression of this microRNA are
highlighted in this model as follows:
a) The promoter region of miR-23b gene is located in
CpG dinucleotide-rich area [7, 8].
b) In the first kilobase, there are two CpG islands with
high CpG density upstream of the transcription start
site (TSS) of miR-23b [7].
c) The regulatory sequence of miR-23b, contains four
putative sites representing response elements for p53
at 1, 8, 10 and 28 kb upstream of the transcription
start site of miR-23b [5, 22, 23] (Fig. 1).
The expression level of miR-23b is decreased in cervical
cancer cell lines due to the methylation of its promoter
region
Bioinformatics analysis and published data allowed us to
identify miR-23b as a candidate for regulation by methy-
lation of its promoter region in cervical cancer. The
methylation status of the promoter region of miR-23b in
HeLa, SiHa, CaSki and C33A cell lines was evaluated by
qRT-PCR. Methylation of the miR-23b promoter was
close to 100 % in the four cell lines (Fig. 2a).
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Fig. 1 Regulatory elements for the expression of miR-23b. a The diagram shows putative p53-binding sites in the miR-23b promoter. The yellow
box represents the location of miR-23b precursor, and the green box symbolizes a binding site for p53 [22]. The pink boxes indicate putative
binding sites for p53 [22, 23]. b CpG islands in the promoter region of miR-23b (blue boxes). The region containing CpG islands was amplified in
this study to determine the methylation status of miR-23b promoter
Fig. 2 miR-23b is deregulated by methylation of its promoter region in cervical cancer cell lines. a The analysis of the methylation status revealed
the almost 100 % of total input DNA had methylated miR-23b gene promoter in C33A, HeLa, SiHa and CaSki cells untreated with 5′-Aza-CdR.
b The relative expression levels of miR-23b were decreased in C33A, HeLa and CaSki cells compared to the levels observed in SiHa cells. c Treatment
with 10 μM 5′-Aza-CdR significantly increased the expression of miR-23b in the four cell lines (weft bars) compared to untreated cells (black bars). The
increased relative expression of miR-23b was ≥50 % over the initial expression (W/T) in C33A, HeLa and CaSki but not in SiHa cells.
*Statistically significant difference (p < 0.05); W/T: Untreated cells
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To investigate if the methylation status corresponds to
the expression level of miR-23b, we determined the rela-
tive expression of miR-23b in HeLa, SiHa, CaSki and
C33A cells. In C33A, HeLa and CaSki cells, the low ex-
pression of miR-23b was negatively related with methy-
lation of the promoter of this miRNA. In contrast, SiHa
cells showed a higher level of miR-23b expression than
C33A, HeLa and CaSki cells (Fig. 2b).
Furthermore, to confirm that methylation is a mechan-
ism that affects the expression of miR-23b in HeLa,
SiHa, CaSki and C33A cells, the cells were exposed to
5′-Aza-CdR, a compound that inhibits DNA methyla-
tion. Compared with untreated cells, the expression level
of miR-23b was higher in all cell lines after treatment
with 5′-Aza-CdR. The increase in the expression of
miR-23b was statistically significant in C33A, HeLa,
SiHa and CaSki cells (p < 0.05), (Fig. 2c).
Effect of exposure of cervical cancer cell lines to 5′-Aza-CdR
on potential molecular targets of miR-23b
The information available in the literature and from the
miRanda and TargedScan databases indicates that uPa,
c-Met and Zeb1 mRNAs contain miR-23b-binding se-
quences (Fig. 3a).
To verify that the observed changes in the expression
level of miR-23b influence the expression of uPa, c-Met
and Zeb1, which are likely targets of this microRNA, the
relative mRNA expression of the three genes was deter-
mined in HeLa, SiHa, CaSki and C33A cells before and
after exposure to 5′-Aza-CdR.
The hypomethylating treatment with 5′-Aza-CdR de-
creased the mRNA expression of uPa in C33A and CaSki
cells but not in HeLa and SiHa cells. Furthermore, the
expression of c-Met was significantly reduced only in
HeLa cells after treatment. The mRNA expression of
Zeb1 decreased only in C33A and CaSki cells, showing
significant changes in both cell lines treated with 5′-
Aza-CdR. In SiHa cells, the expression levels of uPa, c-
Met and Zeb1 increased significantly after exposure to
5-Aza-CdR. The expression of these genes in SiHa cells
may be dysregulated by epigenetic factors among other
modulation mechanisms, (Fig. 3b, c and d).
Expression of miR-23b in scrapes from non-SILs, with
premalignant lesions and cervical cancer
To investigate whether the expression level of miR-23b
was similar in cell lines and in samples from the cervix,
we analyzed cervical scrapes from non-SILs (n = 18) and
tissues from patients diagnosed with LSILs (n = 19),
HSILs (n = 7) or cervical cancer (n = 28), all patients
were infected with HPV16.
The expression of miR-23b was significantly lower in
non-SIL samples (p < 0.05) and in cervical cancer tissues
(p < 0.05) than in tissues from patients diagnosed with
LSIL and HSIL, (Fig. 4).
Risk analysis for the expression of miR-23b indi-
cated that the decrease in the expression levels of
miR-23b in precursor lesions with HPV16 increased
the risk of developing cervical cancer by 36-fold (OR = 36;
95 % CI =6.7-192.6; p < 0.05) (Table 1).
Discussion
Although cervical cancer is one of the most widely stud-
ied tumor models, the role played by epigenetic factors
such as the expression of miRNAs and DNA methyla-
tion in tumorigenesis is not yet fully understood.
The most significant findings of this study were as fol-
lows: 1) the miR-23b promoter is methylated in cervical
cancer cell lines; 2) the expression of miR-23b is low in
cervical cancer cell lines; 3) the expression of miR-23b
increases significantly in HeLa, SiHa, CaSki and C33A
cells after treatment with 5′-Aza-CdR; 4) the expression
of miR-23b is higher in LSIL than in HSIL and cervical
cancer, that is, it decreases as the grade of the lesion in-
creases; 5) in biopsies positive for HPV16 cervical can-
cer, the expression level of miR-23b is similar to that
found in HeLa, SiHa, CaSki and C33A cell lines, and 6)
the expression of uPa, c-Met and Zeb1, which are likely
targets for miR-23b, is different among cervical cancer
cell lines.
Our results on the methylation of miR-23b in cervical
cancer cell lines are consistent with those found by
Majid et al., in prostate cancer cell lines and tumor tis-
sues. In cervical cancer, it is likely that the expression of
miR-23b is also regulated by dinucleotides methylation
in the CpG islands located upstream of the TSS within
of its promoter.
Corresponding to the methylation level of the miR-23b
promoter, which is close to 100 %, the expression of
miR-23b was found to be low in cervical cancer cell
lines, suggesting that methylation is the mechanism of
regulation of the expression of miR-23b in these cells.
Interestingly, we found that in CaSki and HeLa cells,
which have a greater number of integrated viral copies,
the expression of miR-23b was decreased more than in
the SiHa cells with fewer integrated copies. While in
C33A cells, which are HPV-negative, the lowest expres-
sion of miR-23b was detected. The difference in the ex-
pression level of miR-23b in the cervical cancer cell lines
can be explained by the functional characteristics of each
cell line and by the different molecular events as follows:
a) tissue origin of each cell line; b) expression of miR-
23b transcription factors; and c) multiple mechanisms of
regulation for genetic expression.
In cells untreated with 5′-Aza-CdR, the miR-23b
expression was higher in SiHa cells than in HeLa, CaSki
and C33A cells, which can be explained, at least in
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part, by the differential expression of transcription
factors that modulate the expression of miR-23b. SiHa
cells express functional p53 protein at higher levels than
in HeLa, CaSki and C33A cells [24]. p53 is a transcrip-
tion factor [24] that modulates the expression of various
genes. Bisio et al. found that miR-23b contains a
consensus sequence with low-affinity binding for p53
upstream of the TSS. The authors concluded that cis
regulation by p53 partially modulates the expression of
miR-23b [22]. In SiHa cells, Au Yeung et al. found that
p53 expression correlates with miR-23b expression when
the HPV16 E6 oncoprotein is silenced [25]. The higher
Fig. 3 Differential mRNA expression of uPa, c-Met and Zeb1 in cervical cancer cell lines treated with 5′-Aza-CdR. a Hybridization sequences
between miR-23b and its potential target mRNAs. b After treatment with 5′-Aza-CdR, the mRNA expression level of uPa decreased in C33A
and CaSki cells. c The expression of c-Met decreased in C33A, CaSki and HeLa cells after exposure to 5′-Aza-CdR and the changes in HeLa
cells were significant. d Treatment with 5′- Aza-CdR significantly decreased Zeb1 expression levels in C33A and CaSki cells. The mRNA expression
levels of GAPDH were used to normalize the data. *Statistically significant difference (p < 0.05); W/T: Untreated cells
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miR-23b expression level in SiHa cells can be a conse-
quence of the p53 expression level.
In C33A cells, p53 is expressed at normal levels but is
not functional because it has a point mutation at codon
273 in an evolutionarily conserved domain. This mutation
results in the substitution of an arginine with a cysteine
[24]. It is likely that mutated p53 is unable to transactivate
miR-23b, which would explain the low levels of this
miRNA in HPV-negative cervical cancer cells. Other fac-
tors that may be influencing the expression of miR-23b
and other microRNAs are as follows: the HPV type; the
number of viral genome copies integrated into the cell
genome [2, 26]; genetic polymorphisms or mutations in
the promoter of the transcription factors that modulate
the expression of miR-23b [27, 28]; defects in the molecu-
lar machinery responsible for the biogenesis of miR-23b
[29, 30]; and the degree of methylation of miR-23b [7, 8].
We found that the expression of miR-23b is higher in
LSILs than in HSILs and cervical cancer, that is, the ex-
pression of this miRNA decreased as the grade of the le-
sion increased. The decreased expression of miR-23b in
biopsies from patients with cervical cancer positive for
HPV-16 was similar to that found in HeLa, SiHa, CaSki
and C33A cells. miR-23b overexpression in LSILs sug-
gested that miR-23b in cervical carcinogenesis is a
tumor suppressor.
The significantly lower miR-23b expression in biopsies
of cervical cancer than in LSILs and HSILs, may be the
result of gradual miR-23b promoter methylation and al-
terations of other gene expression regulatory mecha-
nisms that are frequent in carcinogenesis. During
tumorigenesis, cells undergoing epithelial-mesenchymal
transition (EMT) are subject to metaplasia, which is
characterized by the loss of E-cadherin (CDH1) expres-
sion [31, 32]. In hepatocellular carcinoma cell lines, de-
creased levels of miR-23b are correlated with the loss of
expression of CDH1 [31, 32]. In endometrial carcinosar-
coma, miR-23b inhibits the expression of mesenchymal
markers [33]. Evidence indicates that CDH1 expression
is downregulated by the snai1 and zeb1 transcription
factors, which are molecular targets of miR-23b [31–33].
The low miR-23b expression in cervical scrapes can be
explained by the origin of the sample, which determines
the type and features of the cells present in the scrape.
Cervical scrapes were obtained from the cell transform-
ation zone (TZ). The transformation zone contains
highly undifferentiated normal cells, such as metaplastic
cells that generally lose cell-cell junctions due to the de-
creased expression of CDH1 [31, 32]. In endothelial
cells, miR-23b expression is negatively associated with
genes that regulate the cell cycle. During the cell cycle,
phosphorylated pRb induces G1/S cell-cycle transition
[34]. Low miR-23b expression is associated with the
phosphorylation status of pRb and indirectly with in-
creased E2F expression, thus promoting the proliferation
of endothelial cells [35]. In metaplastic cervical cells, the
decreased miR-23b expression may be correlated with
continuous pRb activity and cell proliferation.
The similarity in miR-23b expression levels between
cervical scrapes and biopsies of cervical cancer may be
the result of the phenotypic similarity of squamocolum-
nar junction cells (also known as TZ) with cancer cells
and HSIL cells. The subset of cuboidal cells in the
squamocolumnar junction, which give rise to cancer,
and the cancerous tissue maintain a common partial
profile of gene expression [36, 37]. A high percentage of
LSIL and HSIL disappear spontaneously [37] and is
highly likely that in such cases the expression level of
miR-23b is increased compared with Non-SIL. Thus, the
expression level of miR-23b in SILs and cervical cancer
agree with a tumor suppressor gene.
Evidence indicates that uPa, c-Met and Zeb1 are im-
portant promoters of tumor phenotype. uPA is a serine
protease that modulates the turnover of the extracellular
matrix and is related to metastatic tumor phenotypes









Low level 2 (7.7 %) 21 (75 %) 36 (6.7-192.6) <0.05
High level 24 (92.3 %) 7 (25 %) 1.0*
SIL LSIL + HSIL, OR Odds ratio
95 % confidence interval
*Reference value
The bold data indicate the frequency of the expression level found in
premalignant lesions and cervical cancer.
Fig. 4 Expression of miR-23b in cervical scrapes from non-SILs and
in tissues from patients diagnosed with LSIL, HSIL and cervical cancer.
The expression of miR-23b was significantly lower in cervical cancer
biopsies compared with LSIL and HSIL tissues. miR-92a was used for
normalization of the data. *Statistically significant difference (p < 0.05)
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[38]. c-Met is recognized as a factor that induces cell mi-
gration, and Zeb1 is recognized as a factor that pro-
motes epithelial-mesenchymal transition [32]. In highly
malignant cervical cancer tissue, the expression of uPA,
the loss of expression of CDH1 and nuclear expres-
sion of snai1 and zeb1 are strongly associated with
advanced stages of cervical cancer and lymph node
metastasis [32, 39].
In this study, the mRNA expression levels of uPa, c-
Met and Zeb1, which are likely targets of miR-23b, were
compared in HeLa, SiHa, CaSki and C33A cells with and
without exposure to 5′-Aza-CdR. The expression levels
of uPa decreased in CaSki and C33A cells after treat-
ment. These findings partially agreed with those re-
ported by Au Yeung et al., who demonstrated that the
overexpression of miR-23b decreases the expression of
uPa in SiHa and CaSki cells. The increase in the expres-
sion of miR-23b after treatment with 5′-Aza-CdR may
not be sufficient to inhibit the expression of uPa in SiHa
and HeLa cells. In contrast, uPa expression is also influ-
enced by the level of expression and activity of its tran-
scription factors [40] as well as by methylation of its
promoter region [41]. In cervical cancer tissue, the HR-
HPV infection and subsequent alteration of miRNA ex-
pression contribute to deregulate the expression of uPa
[25]. However, there is still insufficient evidence to state
that miR-23b directly regulates the expression of uPa in
this tissue.
The expression level of c-Met was significant lowest in
HeLa cells after treatment with 5′-Aza-CdR, which
agreed with data reported by Salvi et al. [38], who pro-
posed that miR-23b is a regulator of c-Met expression.
Although zeb1 is a direct target of miR-23b in bladder
cancer [42], there are no current studies that support
this theory in cervical cancer. We found that the expres-
sion levels of Zeb1 decrease significantly in C33A and
CaSki cells after being treated with 5′-Aza-CdR, suggest-
ing that miR-23b is involved in regulating the expression
of Zeb1 in these cells. Interestingly, in SiHa cells, the
hypomethylating treatment resulted in increased expres-
sion of uPa, c-Met and Zeb1, thereby suggesting that
other molecular mechanisms affected by changes in the
levels of DNA methylation independent of miR-23b are
involved in regulating these genes in SiHa cells.
To explain the differential expression of uPa, c-Met
and Zeb1 in cervical cancer cell lines, it should be noted
that miRNAs repress or stimulate gene expression in re-
sponse to specific cellular conditions, sequences and co-
factors. The biological outcome of the miRNA-mRNA
interaction is influenced by the following factors: the
percentage of base pairing between the miRNA and tar-
get site; the number and relative position of target sites
for the same miRNA; accessibility of the site; sequences
flanking the target site; and the mRNA secondary
structure, which may influence the hybridization se-
quences [43]. Moreover, Vasudevan and Steitz reported
that the gene repression mediated by a miRNA may be
reversible [44]. Thus, the expression of uPa, c-Met and
Zeb1, which are likely targets of miR-23b, can be the re-
sult of specific features of each cell type, but it is also
likely that some of these mRNAs were translated into
protein at the time of RNA collection. More detailed
studies are needed to determine if uPa, c-Met and Zeb1
are genes regulated by miR-23b in cervical cancer.
Conclusions
In cervical cancer cell lines, miR-23b expression is regu-
lated by its promoter methylation, and is likely the same
process that occurs in cervical carcinogenesis. The de-
crease in miR-23b expression level is associated with
cervical cancer, suggesting that this miRNA is a tumor
suppressor in this cancer. The expression of uPa, c-Met
and Zeb1 in cervical cancer cell lines is likely influenced
by miR-23b, and the difference in the result of the
miRNA-mRNA interaction is determined by factors re-
lated to the specific microenvironment of each cell type,
with unique recognition sequences, cofactors and events
that influence the biological outcome.
Material and methods
Culture of cervical cancer cell lines
The following cell lines were used: HeLa (50 copies of
integrated HPV 18), SiHa (1–2 copies of integrated
HPV16), CaSki (450 to 600 copies of integrated HPV16)
and C33A (HPV-negative). The cells were cultured in
Dulbecco′s modified Eagle medium (DMEM) supple-
mented with fetal bovine serum (10 %) and penicillin/
streptomycin (1 %) (Invitrogen, Carlsbad, CA, USA).
The cells were incubated at 37 °C in humidified atmos-
phere with 5 % CO2 [15, 45].
Treatment of cell lines with 5′-Aza-2-deoxycytidine
(5-Aza-CdR)
Cells were seeded in 6-well plates (25 × 103 cells/well)
and cultured for 72 h before treatment. The cells were
treated with 10 μM 5-Aza-CdR dissolved in DMSO and
added to fresh culture medium. The cultures were incu-
bated at 37 °C in 5 % CO2 for 24 h. The treatment was
then repeated, and the incubation was continued for an
additional 24 h under the same conditions [46, 47]. The
assay was performed in triplicate for each cell line. Un-
treated cells were included as a control [45].
Patients and cell or cervical tissue samples
We studied 54 biopsies from women with cytopathologi-
cal and histopathological diagnosis of squamous intrae-
pithelial lesions (SILs) or cervical cancer with infection
by HPV16. Of these biopsies, 19 were of low-grade
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squamous intraepithelial lesions (LSILs), 7 were of high-
grade squamous intraepithelial lesions (HSIL) and 28
were of cervical cancer. The samples were obtained dur-
ing routine screening for detection of premalignant le-
sions or cervical cancer at the State Cancer Institute
“Dr. Arturo Beltran Ortega” in Acapulco, Guerrero. We
included 18 cervical scrapings from women who had
cervical cytologies without squamous intraepithelial le-
sions (non-SILs) and who were infected with or without
HPV16. These women attended the Immunohistochemis-
try and Cytopathology Laboratory of the Autonomous
University of Guerrero (Chilpancingo, Guerrero, Mexico)
for timely detection of cervical cancer.
Before sampling, all women signed an informed con-
sent to participate in the study.
Extraction and purification of nucleic acids
Extraction of total RNA and DNA from the cell lines be-
fore and after treatment with 5-Aza-CdR as well as from
cervical samples was performed with TRIzol reagent ac-
cording to the manufacturer’s instructions. The integrity
of both nucleic acids was determined by electrophoretic
shift in a 1 % agarose gel [48]. The DNA was stored
at −20 °C, and the RNA was stored at −70 °C.
Detection and typing of HPV16
Detection and typing of HPV was performed using
the INNO-LiPA genotyping extra kit (Innogenetics,
Barcelona, Spain) according to the manufacturer’s
instructions.
Methylation analysis of miR-23b by RT-PCR
The methylation status of the promoter region of miR-
23b was determined using the Human cancer miRNA
EpiTect Methyl II Signature PCR Array® (QIAGEN Sci-
ences, Maryland, USA) following the manufacturer’s in-
structions. Briefly, this assay was based on the digestion of
methylated and unmethylated DNA using methylation-
sensitive and methylation-dependent restriction enzymes.
The DNA that remained after digestion was added to the
matrix. The ABI 7500 system for real-time PCR was used
to read the plates. The relative amount of methylated and
unmethylated DNA was calculated using the standard
ΔCt method, normalizing the amount of DNA in each di-
gestion against the total amount of input DNA in a null
digestion using an Excel spreadsheet provided by the
manufacturer.
Quantitative analysis of miR-23b expression by RT-PCR
The expression of miR-23b was determined using the ABI
7500 system for real-time PCR (Applied Biosystems, Foster
City, CA). Reverse transcription was performed using
10 ng of total RNA. The expression of miR-23b (000400,
AUCACAUUGCCAGGGAUUACC) was measured using
TaqMan microRNA assays following the manufacturer’s
instructions (Applied Biosystems). The expression of miR-
92a (000431, UAUUGCAUUGUCCCGGCCUGU) was
used as an internal reference for the expression of miR-
23b. The relative expression of both miRNAs was analyzed
by the comparative Ct method.
Quantitative polymerase chain reaction (qPCR) assays of
upa, c-met and zeb1
The qPCR assays were performed according to the man-
ufacturer’s instructions with a One-Step qRT-PCR kit
(KAPA SYBR® FAST, Boston, Massachusetts, USA). Using
qPCR assays, we assessed mRNA expression levels of the
following genes: uPa (5′-GTCGTGAGCGACTCCAAA
GGCA-3′ and 5′- GGGCAGTTGCACCAGTGAATG
T-3′), c-Met (5′-TATTTCCCAGATCATCCATTGCA-3′
and 5′- AATGTAGGACTGGTCCGTCAAAA-3′) and
Zeb1 (5′- GCACCTGAAGAGGACCAGAG-3′ and 5′- T
GCATCTGGTGTTCCATTTT-3′). We used GAPDH (5′
GGTGAAGGTCGGTGTGAACG-3′ and 5′ CTCGCTC
CTGGAAGATGGTG-3′) as the internal reference. The
thermal cycling profile was as follows: cDNA synthesis
step was performed using 200 ng of total RNA at 42 °C
for 5 min, followed by an inactivation RT step at 95 °C for
5 min, and 40 cycles of a denaturation step at 95 °C for
3 s, an annealing/extension step at 60 °C for 30 s, and a
dissociation step according to the instrument guidelines.
The qPCR assay was independently repeated three times
using the StepOne system for real-time PCR (Applied Bio-
systems, Foster City, CA). The relative expression of uPa,
c-Met and Zeb1 was analyzed by the comparative Ct
method.
Data analysis
Using the STATA statistical package (version 9.2), we
determined the frequency of methylation of the pro-
moter region of miR-23b, and the same statistical pack-
age was used to determine the expression changes of
miR-23b, uPa, c-Met and Zeb1 between cells treated
with 5′-Aza-CdR and untreated cells. Fisher’s exact test
was used to compare the differences between the two
conditions. The median and interquartile range of the
miR-23b expression was determined, and the difference
between groups was calculated by the Mann-Whitney’s
test. The association between the expression of miR-23b
and the presence of cervical cancer was determined by
logistic regression with a confidence level of 95 %. A
value of p < 0.05 was considered statistically significant.
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